炎症性腸疾患の世界市場：洞察、競合情勢、市場予測：2030年

世界の炎症性腸疾患（IBD）の市場規模は、2024年～2030年の予測期間中に5.72％のCAGRで拡大すると予測されています。IBD市場は、クローン病（CD）や潰瘍性大腸炎（UC）を含むIBDの有病率の上昇、IBDのリスク因子の増加、IBD治療薬の臨床試験数の増加、IBD治療薬や診断機器の安全性と使いやすさの向上への注目の高まりなどの要因によってプラスの成長が促進されており、予測期間（2024年～2030年）中にIBD市場の顕著な収益成長をもたらすと期待されています。

クローン病や潰瘍性大腸炎を含むIBDの有病率の上昇は、IBD市場の成長を促進する主な要因の1つです。欧州クローン病・潰瘍性大腸炎協会連合（European Federation of Crohn's and Ulcerative Colitis Associations 2022）によると、世界で約1,000万人が炎症性腸疾患に苦しんでいます。

Crohn's &Colitis Australia 2022によると、2022年にはオーストラリアで約10万人から16万人がクローン病と潰瘍性大腸炎を患っていると推定され、IBDの世界の疾病負担に拍車をかけています。

喫煙、食習慣の乱れ、家族歴、非ステロイド性抗炎症薬（NSAIDs）などの薬剤の使用、大気汚染、ストレス、うつ病など、IBD発症の危険因子が増加していることも、IBDの診断機器や薬剤の需要を増加させ、IBDの市場成長にプラスの影響を与えています。世界各国における喫煙人口の増加は、IBDの全体的な負担を増加させる。例えば、Nanny State Index（NSI）2022によると、オーストリアの喫煙率は2020年には26.40%でした。煙のない世界のための財団（Foundation for a Smoke-Free World 2022）が報告したデータによると、2019年のブラジルの成人喫煙者は2,040万人となっています。

当レポートでは、世界の炎症性腸疾患市場について調査し、市場の概要とともに、タイプ別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 炎症性腸疾患（IBD）市場レポートのイントロダクション

第2章 炎症性腸疾患（IBD）市場のエグゼクティブサマリー

第3章 規制分析

第4章 炎症性腸疾患（IBD）市場の主な要因分析

• 炎症性腸疾患（IBD）市場の促進要因
• 炎症性腸疾患（IBD）市場の抑制要因と課題
• 炎症性腸疾患（IBD）市場の機会

第5章 炎症性腸疾患（IBD）市場におけるポーターのファイブフォース分析

第6章 炎症性腸疾患（IBD）市場に対するCOVID-19の影響分析

第7章 炎症性腸疾患（IBD）市場概要

• タイプ別
• 地域別

第8章 炎症性腸疾患（IBD）市場における企業と製品プロファイル

• AbbVie Inc.
• Janssen Global Services, LLC
• Takeda Pharmaceutical Company Limited
• Bristol Myers Squibb
• Pfizer Inc.
• Johnson & Johnson Services
• Novartis AG
• UCB S.A., Belgium
• F. Hoffmann-La Roche AG
• Ferring B.V.
• JSR Life Sciences, LLC
• Prometheus Laboratories
• Actim Oy
• Thermo Fisher Scientific
• BUHLMANN
• DiaSorin S.p.A.
• Quidel Corporation
• ALPCO
• CERTEST BIOTEC
• Medtronic

第9章 KOL の見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Inflammatory Bowel Disease (IBD)Market
• Table 3: Inflammatory Bowel Disease (IBD) Market in Global (2021-2030)
• Table 4: Inflammatory Bowel Disease (IBD) Market in Global by Type (2021-2030)
• Table 5: Inflammatory Bowel Disease (IBD) Market in Global by Geography (2021-2030)
• Table 6: Inflammatory Bowel Disease (IBD) Market in North America (2021-2030)
• Table 7: Inflammatory Bowel Disease (IBD) Market in North America by Country (2021-2030)
• Table 8: Inflammatory Bowel Disease (IBD) Market in the US (2021-2030)
• Table 9: Inflammatory Bowel Disease (IBD) Market in Canada (2021-2030)
• Table 10: Inflammatory Bowel Disease (IBD) Market in Mexico (2021-2030)
• Table 11: Inflammatory Bowel Disease (IBD) Market in Europe (2021-2030)
• Table 12: Inflammatory Bowel Disease (IBD) Market in Europe by Country (2021-2030)
• Table 13: Inflammatory Bowel Disease (IBD) Market in France (2021-2030)
• Table 14: Inflammatory Bowel Disease (IBD) Market in Germany (2021-2030)
• Table 15: Inflammatory Bowel Disease (IBD) Market in the United Kingdom (2021-2030)
• Table 16: Inflammatory Bowel Disease (IBD) Market in Italy (2021-2030)
• Table 17: Inflammatory Bowel Disease (IBD) Market in Spain (2021-2030)
• Table 18: Inflammatory Bowel Disease (IBD) Market in the Rest of Europe (2021-2030)
• Table 19: Inflammatory Bowel Disease (IBD) Market in APAC (2021-2030)
• Table 20: Inflammatory Bowel Disease (IBD) Market in APAC by Country (2021-2030)
• Table 21: Inflammatory Bowel Disease (IBD) Market in China (2021-2030)
• Table 22: Inflammatory Bowel Disease (IBD) Market in Japan (2021-2030)
• Table 23: Inflammatory Bowel Disease (IBD) Market in India (2021-2030)
• Table 24: Inflammatory Bowel Disease (IBD) Market in Australia (2021-2030)
• Table 25: Inflammatory Bowel Disease (IBD) Market in South Korea (2021-2030)
• Table 26: Inflammatory Bowel Disease (IBD) Market in the Rest of APAC (2021-2030)
• Table 27: Inflammatory Bowel Disease (IBD) Market in the Rest of the World (2021-2030)
• Table 28: Inflammatory Bowel Disease (IBD) Market in RoW by Region (2021-2030)
• Table 29: Inflammatory Bowel Disease (IBD) Market in the Middle East (2021-2030)
• Table 30: Inflammatory Bowel Disease (IBD) Market in Africa (2021-2030)
• Table 31: Inflammatory Bowel Disease (IBD) Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Inflammatory Bowel Disease (IBD)Market
• Figure 3: Inflammatory Bowel Disease (IBD) Market in Global (2021-2030)
• Figure 4: Inflammatory Bowel Disease (IBD) Market in Global by Type (2021-2030)
• Figure 5: Inflammatory Bowel Disease (IBD) Market in Global by Geography (2021-2030)
• Figure 6: Inflammatory Bowel Disease (IBD) Market in North America (2021-2030)
• Figure 7: Inflammatory Bowel Disease (IBD) Market in North America by Country (2021-2030)
• Figure 8: Inflammatory Bowel Disease (IBD) Market in the US (2021-2030)
• Figure 9: Inflammatory Bowel Disease (IBD) Market in Canada (2021-2030)
• Figure 10: Inflammatory Bowel Disease (IBD) Market in Mexico (2021-2030)
• Figure 11: Inflammatory Bowel Disease (IBD) Market in Europe (2021-2030)
• Figure 12: Inflammatory Bowel Disease (IBD) Market in Europe by Country (2021-2030)
• Figure 13: Inflammatory Bowel Disease (IBD) Market in France (2021-2030)
• Figure 14: Inflammatory Bowel Disease (IBD) Market in Germany (2021-2030)
• Figure 15: Inflammatory Bowel Disease (IBD) Market in the United Kingdom (2021-2030)
• Figure 16: Inflammatory Bowel Disease (IBD) Market in Italy (2021-2030)
• Figure 17: Inflammatory Bowel Disease (IBD) Market in Spain (2021-2030)
• Figure 18: Inflammatory Bowel Disease (IBD) Market in the Rest of Europe (2021-2030)
• Figure 19: Inflammatory Bowel Disease (IBD) Market in APAC (2021-2030)
• Figure 20: Inflammatory Bowel Disease (IBD) Market in APAC by Country (2021-2030)
• Figure 21: Inflammatory Bowel Disease (IBD) Market in China (2021-2030)
• Figure 22: Inflammatory Bowel Disease (IBD) Market in Japan (2021-2030)
• Figure 23: Inflammatory Bowel Disease (IBD) Market in India (2021-2030)
• Figure 24: Inflammatory Bowel Disease (IBD) Market in Australia (2021-2030)
• Figure 25: Inflammatory Bowel Disease (IBD) Market in South Korea (2021-2030)
• Figure 26: Inflammatory Bowel Disease (IBD) Market in the Rest of APAC (2021-2030)
• Figure 27: Inflammatory Bowel Disease (IBD) Market in the Rest of the World (2021-2030)
• Figure 28: Inflammatory Bowel Disease (IBD) Market in RoW by Region (2021-2030)
• Figure 29: Inflammatory Bowel Disease (IBD) Market in the Middle East (2021-2030)
• Figure 30: Inflammatory Bowel Disease (IBD) Market in Africa (2021-2030)
• Figure 31: Inflammatory Bowel Disease (IBD) Market in South America (2021-2030)
• Figure 32: Market Drivers
• Figure 33: Market Barriers
• Figure 34: Marker Opportunities
• Figure 35: PORTER'S Five Force Analysis

Inflammatory Bowel Disease (IBD) Market By Type (Diagnosis [Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Endoscopy, Blood Test, Stool Test, Immunoassays, And Others] And Treatment [Drug Class {Anti-Inflammatory Agents, Immunosuppressant, Analgesics, Antibiotics, And Others} And Surgical]), by geography, is estimated to register a remarkable CAGR during the forecast period from 2024-2030 owing to the rising number of patients suffering from inflammatory bowel disease and increasing pharmaceutical trials for IBD drugs

The global inflammatory bowel disease (IBD) market is estimated to grow at a CAGR of 5.72% during the forecast period from 2024 to 2030. The IBD market is slated to witness prosperity owing to factors such as the rising prevalence of IBD including Crohn's Disease (CD) and Ulcerative Colitis (UC), increasing risk factors for IBD, increasing number of clinical trials for IBD drugs, and the growing focus on improving the safety and usability of IBD drugs and diagnostic devices are further expected to result in the appreciable revenue growth in the IBD market during the forecast period (2024-2030).

Inflammatory Bowel Disease (IBD) Market Dynamics:

The rising prevalence of IBD including Crohn's Disease and Ulcerative Colitis is one of the major factors driving the growth of the IBD market. According to the European Federation of Crohn's and Ulcerative Colitis Associations 2022, worldwide around 10 million people are suffering from inflammatory bowel disease.

As per Crohn's & Colitis Australia 2022, it was estimated that around 100,000 to 160,000 people were living with Crohn's disease and Ulcerative Colitis in Australia in 2022, thus adding to the global disease burden of IBD.

The rising number of risk factors including smoking, poor eating habits, family history, use of drugs such as Non-steroidal Anti-inflammatories (NSAIDs), air pollution, stress, and depression among others for IBD development is also going to increase the demand for diagnostic devices and medications for IBD, positively impacting the market growth for IBD. The increasing rate of smoking population in multiple countries around the world increases the overall burden of IBD. For instance, as per the Nanny State Index (NSI) 2022, the rate of people smoking in Austria was 26.40% in 2020. As per the data reported by Foundation for a Smoke-Free World 2022, there were 20.4 million adult smokers in Brazil in 2019.

Also, the use of NSAIDs which are often taken for the treatment and management of several inflammatory conditions is highly associated with the occurrence of IBD. NSAIDs may trigger the disease activity in both Crohn's disease and Ulcerative Colitis. These drugs can result in a frequent and early relapse of IBD. Thereby, accelerating the demand for IBD drugs and diagnostic devices.

The increasing number of pharmaceutical trials for inflammatory bowel disease is likely to assist the growth of the inflammatory bowel disease market. For example, in May 2022, the pivotal, Phase III LUCENT-2 study of Eli Lilly and Company, involving patients with Ulcerative Colitis (UC) who were treated with mirikizumab for 12 weeks witnessed statistically superior and clinically significant improvements at one year compared to placebo across all important secondary endpoints, including bowel urgency severity, and the primary endpoint of clinical remission.

Also, in March 2022, Pfizer Inc. announced positive Phase III results from the study of etrasimod which is an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator, in development, for the treatment of moderately to severely active Ulcerative Colitis (UC).

However, side effects associated with IBD drugs and stringent regulatory challenges for IBD drugs and diagnostic devices may act as a restraint in the growth of the inflammatory bowel disease market.

The inflammatory bowel disease market reported a short period of restraint in the market growth owing to the implementation of the lockdown as a necessary step to stop the spread of COVID-19 infection. This led to a decline in the development and manufacturing of IBD drugs owing to a shortage of raw materials. Also, the manufacturing and supply of diagnostic devices for IBD were affected. Moreover, due to shifted focus on first treating patients with COVID-19 infection, the diagnosis and treatment of IBD-suspected patients were halted. However, with the resumption of activities across industries including the healthcare and pharmaceutical sector, there has been a rising demand for the IBD owing to the resumption of activities. The post-COVID scenario is going to be uplifting for the IBD market during the forecast period from 2024-2030.

Inflammatory Bowel Disease (IBD) Market Segment Analysis:

IBD Market by Type (Diagnosis [Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Endoscopy, Blood Test, Stool Test, Immunoassays, and Others] and Treatment [Drug Class {Anti-Inflammatory Agents, Immunosuppressant, Analgesics, Antibiotics, and Others} and Surgical]), Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the type segment of the IBD market, the endoscopy category under-diagnosis is projected to register a significant growth in revenue in the IBD market during the forecast period (2024-2030).

This can be ascribed to the advantages associated with the various endoscopic methods in the diagnosis, treatment, and management of inflammatory bowel disease.

Endoscopic methods including colonoscopy, esophagogastroduodenoscopy, sigmoidoscopy, and capsule endoscopy are the key diagnostic methods utilized for the accurate diagnosis of IBD. Diagnosis through these methods helps in the easy differentiation of Crohn's disease (CD) with that from Ulcerative Colitis (UC).

Ileocolonoscopy which is colonoscopy with ileoscopy is considered the gold standard method for the detection and diagnosis of inflammatory bowel disease. Through ileocolonoscopy, the most severely or commonly affected areas of the bowel in patients with IBD can be easily visualized.

Esophagogastroduodenoscopy is highly recommended in pediatric patients in whom IBD is suspected and it helps to establish a definitive diagnosis for both Crohn's disease (CD) and Ulcerative Colitis (UC).

Sigmoidoscopy assists in the examination of IBD in the colon and rectum. Capsule endoscopy offers visualization of the entire length of the small bowel in suspected IBD patients in a comparatively less invasive manner. For example, PillCam(TM) SB 3 by Medtronic is a minimally invasive capsule endoscopy system with an ingestible camera in a capsule that allows visualization of the small bowel and assists in the diagnosis of Crohn's disease.

Therefore, considering the advantages associated with endoscopic methods and their growing popularity among the end-users, this product category is expected to generate considerable revenue thereby pushing the overall growth of the global IBD market during the forecast period.

North America is expected to dominate the overall Inflammatory Bowel Disease (IBD) Market:

Among all the regions, North America is expected to lead in revenue generation in the global IBD market. This can be ascribed to the increasing prevalence of IBD across the region, and a highly potent market in terms of product development and launches, initiatives by government and non-government organizations for IBD patients, and the local presence of key market players among other factors in the region.

The rising number of cases of IBD in the region is one of the major factors driving the growth of the inflammatory bowel disease market. For instance, as per the Centers for Disease Control and Prevention 2022, about 3 million people are living with IBD in the United States. As per the same source, around 80,000 children are expected to be suffering from IBD in the US. This, therefore, indicates the growing need for diagnostic tools and technologies as well as medications for proper diagnosis, treatment, and management of the disease.

The rising number of initiatives by the government and non-government organizations such as research funding in the region is another possible factor affecting the growth of the IBD market. Crohn's & Colitis Foundation is a non-profit organization involved in sponsoring basic and clinical research happening in relation to inflammatory bowel disease. For instance, In May 2022, Progenity, Inc., a biotechnology company, received funding from the Crohn's & Colitis Foundation's IBD Ventures program to further develop Progenity's first-in-class oral Drug Delivery System (DDS) for delivery of targeted therapeutics for IBD.

Earlier, in January 2022, to potentially create the first clinical lab test to forecast disease course in young patients with Crohn's disease and response to therapy, the Crohn's & Colitis Foundation partnered with LifeArc, an independent medical research charity that promotes translation of early science into health care treatments or diagnostics. The clinicians would benefit from a predictive test that could properly predict which kids may experience issues and which patients will benefit from anti-TNF therapy.

Hence, the above-mentioned factors are expected to bolster the growth of the IBD market in the United States during the forecast period.

Inflammatory Bowel Disease (IBD) Market Key Players:

Some of the key market players operating in the IBD market include Thermo Fisher Scientific, JSR Life Sciences, LLC, Novartis AG, AbbVie Inc., Janssen Global Services, LLC, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb, Pfizer Inc., Johnson & Johnson Services, UCB S.A., Belgium, F. Hoffmann-La Roche AG, Ferring B.V., Prometheus Laboratories, Actim Oy, DiaSorin S.p.A., BUHLMANN, Quidel Corporation, ALPCO, CERTEST BIOTEC, Medtronic, and others.

Recent Developmental Activities in the Inflammatory Bowel Disease (IBD) Market:

In March 2022, AbbVie received the US Food and Drug Administration (FDA) approval for RINVOQ® (upadacitinib) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients.

In May 2022, Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has approved Zeposia® for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).

Key Takeaways from the Inflammatory Bowel Disease (IBD) Market Report Study

• Market size analysis for current IBD market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the IBD market.
• Top key product developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the global IBD market.
• Various opportunities available for the other competitor in the IBD market space.
• What are the top-performing segments in 2023? How these segments will perform in 2027.
• Which are the top-performing regions and countries in the current IBD market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for IBD market growth in the coming future?

Target Audience who can be benefited from this Inflammatory Bowel Disease (IBD) Market Report Study

• IBD drugs and diagnostic devices providers
• Research organizations and consulting companies
• IBD -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in IBD drugs and diagnostic devices
• Various distribution channels who want to know more about the IBD market and latest product innovations and developments in the IBD market.

Frequently Asked Questions for the Inflammatory Bowel Disease (IBD) Market:

1. What is inflammatory bowel disease (IBD)?

IBD associated with chronic inflammation in the gastrointestinal tract (GI) includes Crohn's disease and Ulcerative Colitis and is characterized by symptoms such as abdominal pain, diarrhea, loss of appetite, mucus or blood in stool, and others.

2. What is the market for global inflammatory bowel disease (IBD)?

The global inflammatory bowel disease (IBD) market is estimated to grow at a CAGR of 5.72% during the forecast period from 2024 to 2030.

3. What are the drivers for the global inflammatory bowel disease (IBD) market?

The IBD market is slated to witness prosperity owing to factors such as the rising prevalence of inflammatory bowel disease, increasing risk factors for IBD, increasing number of pharmaceutical trials for IBD drugs, and the growing focus on improving the safety, affordability, and usability of IBD drugs and diagnostic devices are further expected to result in the appreciable revenue growth in the IBD market during the forecast period (2024-2030).

4. Who are the key players operating in the global inflammatory bowel disease (IBD) market?

Some of the key market players operating in the IBD market include Thermo Fisher Scientific, JSR Life Sciences, LLC, Novartis AG, AbbVie Inc., Janssen Global Services, LLC, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb, Pfizer Inc., Johnson & Johnson Services, UCB S.A., Belgium, F. Hoffmann-La Roche AG, Ferring B.V., Prometheus Laboratories, Actim Oy, DiaSorin S.p.A., BUHLMANN, Quidel Corporation, ALPCO, CERTEST BIOTEC, Medtronic, and others.

5. Which region has the highest share in the inflammatory bowel disease market?

North America is expected to dominate the overall IBD during the forecast period, 2024 to 2030. This can be ascribed to the increasing research and development activities w.r.t. to inflammatory bowel disease in the region, the increasing number of patients suffering from Crohn's disease and Ulcerative Colitis, high-tech medical facilities, government initiatives, and a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.

Table of Contents

1.Inflammatory Bowel Disease (IBD) Market Report Introduction

2. Inflammatory Bowel Disease (IBD) Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

4. Inflammatory Bowel Disease (IBD) Market Key Factors Analysis

• 4.1. Inflammatory Bowel Disease (IBD) Market Drivers
  • 4.1.1. Rising prevalence of inflammatory bowel disease (IBD)
  • 4.1.2. The increasing number of risk factors for IBD
  • 4.1.3. The increasing number of pharmaceutical trials for IBD drugs
• 4.2. Inflammatory Bowel Disease (IBD) Market Restraints and Challenges
  • 4.2.1. Side effects associated with IBD drugs
  • 4.2.2. Stringent regulatory challenges
• 4.3. Inflammatory Bowel Disease (IBD) Market Opportunities
  • 4.3.1. Technological advancements such as the use of artificial intelligence (AI) in IBD diagnosis

5. Inflammatory Bowel Disease (IBD) Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Inflammatory Bowel Disease (IBD) Market

7. Inflammatory Bowel Disease (IBD) Market Layout

• 7.1. By Type
  • 7.1.1. Diagnosis
    • 7.1.1.1. Magnetic Resonance Imaging (MRI)
    • 7.1.1.2. Computed Tomography (CT)
    • 7.1.1.3. Endoscopy
    • 7.1.1.4. Blood Test
    • 7.1.1.5. Stool Test
    • 7.1.1.6. Immunoassays
    • 7.1.1.7. Others
  • 7.1.2. Treatment
    • 7.1.2.1. Drug Class
    • 7.1.2.1.1. Anti-inflammatory Agents
    • 7.1.2.1.2. Immunosuppressant
    • 7.1.2.1.3. Analgesics
    • 7.1.2.1.4. Antibiotics
    • 7.1.2.1.5. Others
    • 7.1.2.2. Surgical
• 7.2. By Geography
  • 7.2.1. North America
    • 7.2.1.1. United States Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)
    • 7.2.1.2. Canada Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)
    • 7.2.1.3. Mexico Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)
  • 7.2.2. Europe
    • 7.2.2.1. France Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)
    • 7.2.2.2. Germany Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)
    • 7.2.2.3. United Kingdom Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)
    • 7.2.2.4. Italy Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)
    • 7.2.2.5. Spain Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)
    • 7.2.2.6. Rest of Europe Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)
  • 7.2.3. Asia-Pacific
    • 7.2.3.1. China Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)
    • 7.2.3.2. Japan Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)
    • 7.2.3.3. India Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)
    • 7.2.3.4. Australia Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)
    • 7.2.3.5. South Korea Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)
    • 7.2.3.6. Rest of Asia Pacific Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)
  • 7.2.4. Rest of the World (RoW)
    • 7.2.4.1. Middle East Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)
    • 7.2.4.2. Africa Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)
    • 7.2.4.3. South America Inflammatory Bowel Disease (IBD) Market in USD million (2021-2030)

8. Inflammatory Bowel Disease (IBD) Market Company and Product Profiles

• 8.1. AbbVie Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Janssen Global Services, LLC
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Takeda Pharmaceutical Company Limited
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Bristol Myers Squibb
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Pfizer Inc.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Johnson & Johnson Services
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Novartis AG
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. UCB S.A., Belgium
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. F. Hoffmann-La Roche AG
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.10. Ferring B.V.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. JSR Life Sciences, LLC
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Prometheus Laboratories
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Actim Oy
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Thermo Fisher Scientific
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. BUHLMANN
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. DiaSorin S.p.A.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Quidel Corporation
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. ALPCO
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. CERTEST BIOTEC
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Medtronic
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us